Advocacy - Tax and Fiscal

Orphan Drug Tax Credit California Company Sign-On Letter – October 2017

October 31, 2017

The Honorable Kevin McCarthy
House Majority Leader
H-107, U.S. Capitol
Washington, D.C. 20515
The Honorable Nancy Pelosi
House Democratic Leader
H-204, U.S. Capitol
Washington, D.C. 20515

Dear Majority Leader McCarthy and Democratic Leader Pelosi,

As leading California companies that are focused on developing treatments and cures for patients afflicted with rare diseases, we write to let you know of our strong support for the Orphan Drug Tax Credit (ODTC), and urge you to ensure it is protected and preserved in any tax reform package considered by Congress.

As you may know, a rare disease or condition is defined as one which affects 200,000 or fewer persons in the United States.  An orphan drug is a therapy treating such a rare disease.  The National Institutes of Health recognizes between 6,000 and 7,000 rare diseases and medical disorders that affect more than 30 million Americans (one in 10).